Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases

US5723122A · kind A · utility

Assignee

• Boehringer Mannheim GmbH · DE

Inventors

• Ulrich Kohnert · Habach, DE
• Anne Stern · Penzberg, DE
• Ulrich Martin · Mannheim, DE
• Stephan Fischer · Weilheim, DE

Key dates

• Filing date: Jun 1, 1995
• Grant date: Mar 3, 1998
• Expiry date: Jun 1, 2015

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to the use of thromboembolic proteins. These contain, as their only structural portion effecting thrombolytic activity, the protease domain of human tissue type plasminogen activator. These derivatives show reduced side effects, such as a reduction in bleeding while. demonstrating remarkable in vivo efficacy. The effect is surprising, given their in vitro properties.